10-Q: PetMed Express Reports Steep Losses, Sales Decline Amid Restatement

PetMed Express, Inc. reported a significant net loss and substantial revenue decline for the quarter and six months ended September 30, 2025, alongside a restatement of prior period financials and a $27.3 million impairment charge.

Summary

• PetMed Express, Inc. (PETS) reported a net loss of $8.5 million for the three months ended September 30, 2025, a significant decline from a net income of $2.3 million in the prior year's restated period.
• Net sales decreased by 23.6% to $44.4 million for the quarter and by 23.1% to $95.5 million for the six months ended September 30, 2025, compared to the restated prior year periods.
• Gross profit fell by 33.9% to $12.4 million for the quarter and by 29.1% to $26.8 million for the six months, with gross margin percentages decreasing to 28.0% and 28.1% respectively.
• The company recognized a $26.7 million goodwill impairment charge and a $0.6 million intangible asset impairment (PCRX trade name) during the first quarter of fiscal 2026, totaling $27.3 million for the six months ended September 30, 2025.
• General and administrative expenses increased by 35.1% to $14.2 million for the quarter and by 76.5% to $27.1 million for the six months, partly due to $2.1 million in professional fees related to a whistleblower investigation.
• Cash and cash equivalents decreased by $18.6 million from $54.7 million at March 31, 2025, to $36.1 million at September 30, 2025.
• Net cash used in operating activities was $14.4 million for the six months ended September 30, 2025, compared to $1.1 million used in the prior year.
• The company restated its unaudited consolidated financial statements for the three and six months ended September 30, 2024, to correct material errors in accounting for vendor-funded programs, which impacted net sales, cost of sales, gross profit, and advertising expenses.
• New customer acquisitions decreased to 58,000 for the quarter (from 77,000) and 143,000 for the six months (from 197,000).
• Recurring net sales, including AutoShip & Save subscriptions and membership revenue, increased as a percentage of total gross sales to 60.8% for the most recent quarter, up from 53.4% in the prior year.

Sentiment

Score: 2

Explanation: The company's financial performance is severely negative, marked by substantial net losses, significant revenue declines, deteriorating gross margins, and a large impairment charge. The restatement of prior financials and ongoing internal control weaknesses further compound the negative sentiment. While there's a slight positive in recurring sales percentage and quarterly customer acquisition cost, the overall picture is dire.

Positives

• Recurring net sales as a percentage of total gross sales increased to 60.8% for the quarter ended September 30, 2025, up from 53.4% in the same period last year, indicating improved customer retention or subscription model adoption.
• Advertising costs of acquiring a new customer decreased to $75 for the quarter ended September 30, 2025, compared to $79 for the prior year quarter, suggesting more efficient variable marketing spend and higher third-party partner funding.

Negatives

• Reported a net loss of $8.5 million for the three months and $42.7 million for the six months ended September 30, 2025, a significant deterioration from net income in the prior year periods.
• Net sales decreased substantially by 23.6% ($13.7 million) for the quarter and 23.1% ($28.7 million) for the six months, driven by reduced advertising, higher consumer promotional usage, and declining prescription medication sales.
• Gross profit decreased by 33.9% ($6.4 million) for the quarter and 29.1% ($11.0 million) for the six months, primarily due to lower sales and higher cost of sales.
• Gross margin percentage declined by 4.3 percentage points to 28.0% for the quarter and 2.3 percentage points to 28.1% for the six months, mainly due to higher freight costs and increased consumer promotional usage.
• General and administrative expenses increased significantly by 35.1% ($3.7 million) for the quarter and 76.5% ($11.8 million) for the six months, partly due to $2.1 million in professional fees related to a whistleblower investigation.
• Incurred a $26.7 million goodwill impairment charge and a $0.6 million intangible asset impairment during the first quarter of fiscal 2026, reflecting a downward revision to forecasts and a sustained decrease in market capitalization.
• Cash and cash equivalents decreased by $18.6 million from March 31, 2025, to September 30, 2025.
• Net cash used in operating activities increased significantly to $14.4 million for the six months ended September 30, 2025, from $1.1 million in the prior year.
• Working capital decreased by $13.3 million from $16.1 million at March 31, 2025, to $2.8 million at September 30, 2025.
• New customer acquisitions declined by 19,000 for the quarter and 54,000 for the six months, indicating challenges in attracting new business.
• The company restated prior period financial statements due to material errors in accounting for vendor payments, rebates, and discounts, raising concerns about financial reporting accuracy.

Risks

• Macroeconomic factors, including inflation, increased interest rates, capital market and supply chain volatility, and geopolitical developments, are expected to continue impacting operations, customer demand, and revenue growth rates for the remainder of fiscal 2026.
• Increased competition and consumers giving more consideration to price may adversely affect future sales.
• Changes in consumer behavior due to macroeconomic factors make future sales challenging to predict, with no guarantees of future sales growth.
• Unsolicited acquisition proposals and attempts to acquire control of the company could cause significant expense, disrupt business, and negatively impact the stock price.
• The company is involved in a class action lawsuit alleging violations of Pennsylvania's Unfair Trade Practices and Consumer Protection Law regarding 'illusory discounts,' with potential, but currently unquantifiable, liability.
• Past settlements with state pharmacy boards and potential future similar actions by other states pose ongoing regulatory and legal risks.
• Challenges in protecting trade or service marks could negatively impact the business.
• The company's disclosure controls and procedures were not effective as of June 30, 2025, due to unremediated material weaknesses in internal control over financial reporting, which could adversely affect the ability to record, process, summarize, and report financial information reliably.

Future Outlook

The company expects macroeconomic factors, including inflation, increased interest rates, capital market and supply chain volatility, and geopolitical developments, to continue impacting its operations, customer demand, and revenue growth rates for the remainder of fiscal 2026. Management cautions that no guarantees can be made that sales will grow in the future, and the current environment may impact revenue growth rates.

Management Comments

• Management believes that the company's cash and cash equivalents currently on hand and expected cash flows from future operations will be sufficient to continue operations for at least the next twelve months.
• Management proactively seeks opportunities to improve the efficiency of operations, realize internal cost savings, including aligning staffing needs, creating a more variable cost structure, and process streamlining.
• The Board of Directors adopted the Rights Agreement to protect the investment of shareholders during a period in which it believes shares do not reflect the inherent value of the business or its long-term growth potential, and during which there have been recent significant accumulations of common stock by certain shareholders.
• The Board of Directors reviews and discusses the capital allocation needs of the Company on a quarterly basis, and on October 26, 2023, elected to suspend the quarterly dividend indefinitely to focus cash on growth and higher return initiatives.

Industry Context

The pet care industry, particularly online pharmacies, faces challenges from macroeconomic factors such as inflation and rising interest rates, which can impact consumer spending patterns. Increased competition and price sensitivity are also noted as potential adverse factors. The company's decline in new customer acquisition and overall sales suggests it may be struggling to adapt to these market dynamics or facing intensified competitive pressures, despite an increase in recurring revenue as a percentage of total sales, which could indicate a shift towards subscription models or loyal customer base focus.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• A class action lawsuit was filed on April 18, 2024, by Timothy Fitchett against the company in Pennsylvania, alleging violations of the Unfair Trade Practices and Consumer Protection Law related to 'illusory discounts.' The company denies liability and intends to defend the action, but cannot determine materiality or estimate potential liability at this time.
• The company has settled complaints with various state pharmacy boards in the past and acknowledges that other states may attempt similar actions in the future.
• The company intends to vigorously defend its trade or service marks, but there is no assurance of success in protecting them.

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Significant net losses, declining share price, and impairment charges negatively impact shareholder value. The Rights Agreement aims to protect shareholders from undervalued acquisitions, but the underlying business performance is a concern. Unsolicited acquisition proposals could create uncertainty but also potential for a premium.
• Employees: Employee severance expenses increased, indicating potential workforce adjustments. The separation agreements with former executives suggest leadership changes.
• Customers: Higher consumer promotional usage and a decline in prescription medication sales suggest potential shifts in customer behavior or competitive pressures. The class action lawsuit alleges misleading pricing practices.
• Creditors: Deteriorating financial performance, including increased cash usage from operations and reduced working capital, could raise concerns for creditors regarding the company's ability to meet short-term obligations, although liquidity is deemed sufficient for 12 months.
• Suppliers: Changes in accounting for vendor-funded programs and declining sales could impact relationships and terms with suppliers.

Next Steps

• The Board will carefully review and consider the unsolicited and non-binding acquisition proposals to determine the course of action in the best interests of the company and its stockholders.
• Management will continue to monitor forthcoming guidance, interpretations, and technical clarifications regarding the One Big Beautiful Bill Act (OBBBA) to assess whether any future adjustments or additional disclosures may be required.
• The company is currently evaluating the impact of adopting ASU 2023-09 (Income Taxes), ASU 2024-03 (Expense Disaggregation Disclosures), and ASU 2025-05 (Credit Losses for Accounts Receivable), and ASU 2025-06 (Internal-Use Software).
• Management will continue to proactively seek opportunities to improve operational efficiency, realize internal cost savings, align staffing needs, create a more variable cost structure, and streamline processes.

Key Dates

Recommendation

The filing reveals a company in significant distress, marked by substantial net losses, a sharp decline in revenue, deteriorating gross margins, and a major goodwill impairment. The restatement of prior financials due to material errors raises serious concerns about financial reporting integrity. While the increase in recurring sales percentage is a minor positive, it is overshadowed by the overall poor performance and significant cash burn from operations. The ongoing material weaknesses in internal controls further erode confidence. Despite unsolicited acquisition proposals, the fundamental business performance is extremely weak, suggesting a high risk of further value erosion for investors. A seasoned investor would likely view this as a strong sell, anticipating continued operational challenges and potential further declines in valuation.

Keywords

PetMed Express, PETS, 10-Q, Quarterly Report, Pet Pharmacy, Online Pet Supplies, Financial Results, Net Loss, Revenue Decline, Goodwill Impairment, Financial Restatement, Corporate Governance, Shareholder Rights Plan, Acquisition Proposals, E-commerce, Pet Care, Veterinary Telehealth, SEC Filing